Navigation Links
Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012

MALVERN, Pa., May 3, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the first quarter 2012 on Thursday, May 10, 2012 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the first quarter 2012.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 10 a.m. ET on Thursday, May 10, 2012.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 10:00 a.m. ET on Thursday, May 10, 2012.  A question and answer session will follow the presentation. 

(Logo: )

Mr. Adrian Adams, Chief Executive Officer and President, will host the conference call.Conference call details:Date:

Thursday, May 10, 2012Time:

10:00 a.m. ETDial-in (U.S.):

866-356-4281Dial-in (International):

617-597-5395Web cast:


AUXILIUMTo access an audio replay of the call:Access number (U.S.):

888-286-8010 Access number (International):

617-801-6888Replay Passcode #:

50696959About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.  Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  Auxilium has three projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease, in phase IIa of development for the treatment of Frozen Shoulder syndrome (Adhesive Capsulitis) and is in phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to announce the first quarter 2012 results; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite.  Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.  A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2011, which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.Contacts:
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
3. Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference
4. Auxilium Pharmaceuticals to Present at the 2012 Cowen Healthcare Conference
5. BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico
6. Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico
7. Auxilium Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
9. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
11. Auxilium Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy ... and funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving ... things from patients including their ability to work and be productive, to do simple ...
(Date:12/1/2015)... ... 2015 , ... Henderson, a town of about 6,300 people, ... a partnership this year with Aeneas Internet and Telephone. , With faster Internet ... entrepreneurs who want to build a business. Whether startups or long established companies, ...
(Date:12/1/2015)... ... ... Integrated Rental Services (“Integrated Rental”), a growing medical equipment ... With support from JII, Integrated Rental is poised for expansion while improving its ... labs and medical facilities across the United States. , General Manager Robert Bean ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
Breaking Medicine News(10 mins):